An 8-Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Efficacy and Safety of Valsartan Administered in Combination With Aliskiren (160/150 mg, 320/300 mg) Versus Valsartan Alone (160 mg, 320 mg) in Patients With Stage 2 Hypertension.
Phase of Trial: Phase IV
Latest Information Update: 29 Apr 2011
At a glance
- Drugs Aliskiren/valsartan; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms VANTAGE
- 10 Jun 2017 Biomarkers information updated
- 20 Oct 2009 Actual patient number (449) added as reported by ClinicalTrials.gov.
- 23 Apr 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.